Inclusion Criteria:  Patients over 18 years of age. Patients with a clinical and histological diagnosis of some mucocutaneous disease. Patients diagnosed with oral lichen planus will be selected according to the American Academy of Oral and Maxillofacial Pathology, pemphigus vulgaris and / or scarring pemphigoid according to the 2015 World Workshop on Oral Medicine. Patients who present GD, that is, erythema, epithelial desquamation, atrophy, painful erosions or ulceration of the free and / or attached gingiva, which is not related to the local accumulation of plaque.  Exclusion Criteria:  Being in cancer treatment with head and neck radiotherapy, chemotherapy or immunotherapy. Being diabetic. Being on topical corticosteroid treatment in the previous 4 weeks or systemic treatment in the previous 8 weeks. Those patients who do not present the anterosuperior sector (from canine to upper canine) or the anteroinferior sector (from canine to lower canine) will also be excluded. Pregnant or breastfeeding. Being a smoker. Use of rinses for plaque control. Being medicated with drugs associated with gingival enlargement such as cyclosporine, calcium channel blockers and phenytoin. To have taken antibiotics and / or anti-inflammatories 3 months before the study. Taking medications capable of producing lichenoid reactions. Patients who do not want to sign the informed consent. Patients with periodontitis according to the consensus criteria of Papapanou et al. 2018 or patients treated for unstable periodontal disease according to the classification of Chapple et al. 2017.